Drug-induced liver injury, viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune liver disease, and other liver injury diseases.
Conditions
Interventions
Control Group:Only conventional liver-protection drugs
experimental group 2:Patients treated with Yinhuang Yanggan Pills
Sponsors
Integrated Traditional Chinese and Western Medicine Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Visited this hospital between January 2015 and December 2025; 2. Age between 18 and 80 years old; 3. Clearly diagnosed with drug-induced liver injury, viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune liver disease, etc., and liver function biochemical test indicators (ALT, AST, GGT, etc.) are abnormal; 4. Received treatment with Yinhuang Yanggan Wan or conventional liver-protecting drugs, with a treatment duration of =3 days; 5. Complete liver function biochemical test records before and after treatment; 6. Complete medical records.
Exclusion criteria
Exclusion criteria: 1. Patients with other severe systemic diseases (e.g., advanced tumors, severe heart and kidney dysfunction); 2. Patients in pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The normalization rate of liver function indicators (ALT, AST, GR, TB, IB, DB) before and after treatment, as well as the reduction compared to baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Efficacy Grade;Improvement of symptoms and signs; | — |
Countries
China
Contacts
Public ContactGao Lei
Integrated Traditional Chinese and Western Medicine Hospital of Southern Medical University
Outcome results
None listed